Number: 201112113 Principal Investigator: Lockhart, A. Craig
Title: An open-label, multi-center Phase I dose-finding study of RAD001 (everolimus, Afinitor®) in combination with BEZ235 in patients with advanced solid tumors
Phase: I Disease Site: Multiple Sites
Participating Site(s):
Main Campus
Map and Directions
Contact: 800-600-3606 or

The purpose of this research study is to find out if the drugs RAD001 (Everolimus, Afinitor®) and BEZ235 given in combination are safe and have beneficial effects in people who have advanced solid tumors. This study has two parts. In the dose-finding part of the study, you will be assessed to find the safety of the starting doses for the drugs RAD001 and BEZ235. Once the right dose is found, then
patients with ER+/HER2- metastatic breast cancer (ER+/HER2- results indicate whether or not different hormones are present in the breast tumor) or metastatic renal cell carcinoma (kidney cancer) will be asked to join the study to learn if the study drugs RAD001 and BEZ235 can slow or prevent the
recurrence of your cancer. This is considered the dose expansion part of the study.
More Information: Entry
Internal Protocol Documents (requires Siteman administrative database password)